The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-07 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In December 2016, it was announced that Monster would replace Sprint Corporation as title sponsor of NASCAR's premier series. NASCAR's chief marketing officer cited Monster's "youthful and edgy" brands a driving force behind the deal. In April 2019, it was reported that NASCAR rejected Monster Energy's offer to extend its sponsorship through 2020 in favor of a new tiered sponsorship model. Monster is endorsed by NASCAR driver Ty Gibbs and sponsors his No. 54 Joe Gibbs Racing car, as well as his Toyota Racing teammate Riley Herbst and his No. 35 23XI Racing car through Terrible Herbst. They are also endorsed by Kurt Busch, who retired due to injuries after the 2022 season. They have also had sponsored Tyler Reddick, Robby Gordon, Ricky Carmichael, and the No. 54 Xfinity Series car of Joe Gibbs Racing/Kyle Busch Motorsports. Monster sponsored Formula 1 team Mercedes-AMG Petronas Motorsport between 2010 and 2023 and was endorsed by the team's drivers, George Russell and seven-time World Champion Lewis Hamilton. Hamilton also has a signature drink with the brand, "LH44". Monster Energy partnered with McLaren from the 2024 season onwards, including introducing a Lando Norris-inspired flavour featuring his helmet design on the can. The company will continue to sponsor Hamilton on a personal level. In September 2026, Monster became a sponsor of LN4 Fusion, a junior-level racing team co-founded by Norris.
Reconnecting after years of estrangement, Enric and Irene confront their abusive past — discovering their father Albert lived a separate wealthy life and that Montserrat has continued her delusional cult. Enric infiltrates the family home during Christmas, exposing Montserrat’s lies, which culminates in Cecilia fleeing the household to join Irene. Following a visionary ayahuasca trip where Enric finally processes his childhood trauma while Irene and Cecilia rebuild their lives.
She also studies antivirals that work through mechanisms other than reverse transcriptase inhibition such as the HIV entry inhibitor maraviroc; she found that genetic variants of CYP3A genes could impact its clearance. Bumpus' lab also found that cytochrome P450 enzymes convert the anti-epileptic valproic acid into byproducts (metabolites) that activate AMPK; they showed that this could reverse the obesity-related problems of fatty liver disease and high blood sugar in mouse models.
=== Venture capital === Verdine has worked in the venture capital industry as a Venture Partner with Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures, and as a Special Advisor to Texas Pacific Group.
Being abandoned for a long time after it closed in 1996, it was then occupied by the Askatasuna Social Center, a non-profit anarchic organisation, hosting since then various activities such as concerts, dinners, seminars and homeless solidarity initiatives.
Sources: en.wikipedia.org
== Scientific approach == In xenobiology, the aim is to design and construct biological systems that differ from their natural counterparts on one or more fundamental levels. Ideally these new-to-nature organisms would be different in every possible biochemical aspect exhibiting a very different genetic code. The long-term goal is to construct a cell that would store its genetic information not in DNA but in an alternative informational polymer consisting of xeno nucleic acids (XNA), different base pairs, using non-canonical amino acids and an altered genetic code. So far cells have been constructed that incorporate only one or two of these features.
=== Former programming === Formerly, Bryant Park hosted New York Fashion Week (NYFW) shows, which took over the park for two weeks in the winter and late summer each year. NYFW, which moved to Bryant Park in 1993, was forced to set fees for its shows after Manhattan Community Board 5 disapproved of a free fashion show on the grounds that three-fourths of profits would go to BPC and only one-fourth to NYC Parks. Dan Biederman of the BPC had called the profits from NYFW "a million dollars I would happily do without," and lamented the fact that NYFW took over the park at two high-traffic periods: late summer and late winter. NYFW moved from Bryant Park in 2010 after disagreements with the BPC.
Hypothyroidism is an endocrine disease in which the thyroid gland does not produce enough thyroid hormones. It can cause a number of symptoms, such as poor ability to tolerate cold, extreme fatigue, muscle aches, constipation, slow heart rate, depression, and weight gain. Occasionally, there may be swelling of the front part of the neck due to goiter. Untreated cases of hypothyroidism during pregnancy can lead to delays in growth and intellectual development in the baby or congenital iodine deficiency syndrome. Worldwide, too little iodine in the diet is the most common cause of hypothyroidism. Hashimoto's thyroiditis, an autoimmune disease wherein the body's immune system reacts to the thyroid gland, is the most common cause of hypothyroidism in countries with sufficient dietary iodine. Less common causes include previous treatment with radioactive iodine, injury to the hypothalamus or the anterior pituitary gland, certain medications, a lack of a functioning thyroid at birth, or previous thyroid surgery. The diagnosis of hypothyroidism, when suspected, can be confirmed with blood tests measuring thyroid-stimulating hormone (TSH) and thyroxine (T4) levels. Salt iodization has prevented hypothyroidism in many populations. Thyroid hormone replacement with levothyroxine treats hypothyroidism. Medical professionals adjust the dose according to symptoms and normalization of the TSH levels. Thyroid medication is safe in pregnancy. Although an adequate amount of dietary iodine is important, too much may worsen specific forms of hypothyroidism.
A morgen ("morning" in Dutch and German) was approximately the amount of land tillable by one man behind an ox in the morning hours of a day. This was an official unit of measurement in South Africa until the 1970s, and was defined in November 2007 by the South African Law Society as having a conversion factor of 1 morgen = 0.856532 hectares. This unit of measure was also used in the Dutch colonial province of New Netherland (later New York and parts of New England).
Sources: en.wikipedia.org
In October 2025, Moore announced an agreement between the state and Constellation Energy that would allow the Conowingo Dam to continue operations for another 50 years, but required the company to spend $341 million on a series of renovations to support fish migration through the damn and limit pollution flowing through it to the lower Susquehanna River and the Chesapeake Bay.
These findings extend the use of MPPT into dermatology and positive effects have been observed in hidradenitis suppurativa. The MPPT technology has been approved in the EU as a "treatment for wounds" and is currently the only wound product with this approval. Other medical devices for wounds are approved to have a certain effect on the wound, e.g. add moisture or remove wound exudate, but they are not recognised as treatments.
== Purpose == Depot injections provide longer duration drug action through slow absorption into the bloodstream. They are usually administered in the muscle, into the skin, or under the skin. The injected medication slowly releases the medication into the bloodstream. It may be used in patients who forget to take their medication; some doctors and patients consider the use of a depot injection to be coercion, and are opposed to their use for that reason.
==== Predictors of greater weight loss ==== Patient selection is an important consideration for any weight loss therapy. The present published literature shows either no influence or conflicting results for patient age, sex, starting weight/BMI on weight loss from ESG. Long-term after care programs have demonstrated benefit for sustained weight loss after ESG, with one study showing that patients who continued after care visits following ESG had 20.5% total body weight loss compared to 16.9% total body weight loss in those who dropped out of long-term follow up programs.
== Tributes == "Referring to the death of Professor Brailsford Robertson yesterday, the Prime Minister (Mr. Scullin) said:— His untimely end has robbed Australia of a brilliant scientist, whose contribution to the Commonwealth's progress would always be remembered. On behalf of the Federal Ministry Mr. Scullin extended his sincere sympathy to Professor Robertson's family, and expressed its appreciation of the great national services which he had rendered." The Argus, 20 January 1930. "Professor Brailsford Robertson was one of Australia's most brilliant scientists. The value of the work he was accomplishing cannot be estimated." Hon. R.L. Butler, Premier of South Australia, 20 January 1930. "The main purpose of [Robertson's] studies was to solve the mystery of physical life in it successive stages of commencement, growth, decline, and cessation, for the benefit of his fellow-men. ... The amount of original work he accomplished in his short life was prodigious. I would be rash to assert that the loss to science, or as I should prefer to say, the loss to humanity, caused by his death is irreparable, but it will probably be a long time before anyone else is able to gather the threads together and produce the fabric he was attempting to weave on his loom." Sir George Murray, Chancellor of the University of Adelaide, 18 March 1932.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.